Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease
2011

Genetic Variants in the Nicastrin Gene and Alzheimer's Disease Risk

Sample size: 671 publication 10 minutes Evidence: moderate

Author Information

Author(s): Michelle K. Lupton, Petroula Proitsi, Makrina Danillidou, Magda Tsolaki, Gillian Hamilton, Richard Wroe, Megan Pritchard, Kathryn Lord, Belinda M. Martin, Iwona Kloszewska, Hilkka Soininen, Patrizia Mecocci, Bruno Vellas, Denise Harold, Paul Hollingworth, Simon Lovestone, John F. Powell

Primary Institution: MRC Centre for Neurodegeneration Research, Institute of Psychiatry, King's College London

Hypothesis

Does rare variation in the Nicastrin gene affect the risk of Alzheimer's disease?

Conclusion

The study identified a rare genetic variant in the Nicastrin gene that is associated with an increased risk of Alzheimer's disease in a specific population.

Supporting Evidence

  • Five SNPs were identified and validated by individual genotyping from 311 cases and 360 controls.
  • Association analysis identified a non-synonymous rare SNP (N417Y) with a statistically higher frequency in cases compared to controls.
  • The odds ratio for the N417Y variant was 3.994, indicating a significant association with Alzheimer's disease risk.
  • The study used an innovative pooling approach and next-generation sequencing to analyze genetic variants.
  • Results suggest that rare genetic variants may contribute to the heritability of Alzheimer's disease.

Takeaway

Scientists looked at a gene called Nicastrin to see if changes in it could make people more likely to get Alzheimer's disease, and they found one change that seems to do just that.

Methodology

The study used pooled DNA from Alzheimer's patients and controls, followed by next-generation sequencing to identify genetic variants.

Potential Biases

Potential biases in sample representation and sequencing errors could affect the results.

Limitations

The study's findings may not be generalizable to all populations due to the specific cohort used.

Participant Demographics

The study included 311 Alzheimer's patients and 360 matched controls from Greece.

Statistical Information

P-Value

0.012

Confidence Interval

1.24–16.12

Statistical Significance

p=0.012

Digital Object Identifier (DOI)

10.1371/journal.pone.0017298

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication